Nanoparticles of cisplatin augment drug accumulations and inhibit multidrug resistance transporters in human glioblastoma cells
Background: Cisplatin (CSP) is a potent anticancer drug widely used in treating glioblastoma multiforme (GBM). However, CSP's clinical efficacy in GBM contrasted with low therapeutic ratio, toxicity, and multidrug resistance (MDR). Therefore, we have developed a system for the active targeting...
Main Authors: | Naseer Maliyakkal, Asmy Appadath Beeran, Nayanabhirama Udupa |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2021-08-01
|
Series: | Saudi Pharmaceutical Journal |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1319016421001286 |
Similar Items
-
In vivo Glioblastoma Therapy Using Targeted Liposomal Cisplatin
by: Ashrafzadeh MS, et al.
Published: (2020-09-01) -
Intelligent polymeric micelles for multidrug co-delivery and cancer therapy
by: Guangping Yu, et al.
Published: (2019-12-01) -
Engineered Biosensors for Diagnosing Multidrug Resistance in Microbial and Malignant Cells
by: Niharika G. Jha, et al.
Published: (2023-02-01) -
Fucoxanthin Inhibits the Proliferation of ABCC2-Over Expressing Cisplatin-Resistance Ovarian Cancer Cells via Inducing Apoptosis
by: Fatemeh Valinezhad Sani, et al.
Published: (2023-07-01) -
Glutamine protects against cisplatin-induced nephrotoxicity by decreasing cisplatin accumulation
by: Hyun-Jung Kim, et al.
Published: (2015-01-01)